{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-012365","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.057861+00:00","generated_at":"2026-06-04T09:55:51.096121+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Absci Q4 net loss $23.5M; initiates IND-enabling for ABS-101; AstraZeneca deal up to $247M","bullets":["FY23 net loss $110.6M, revenue $5.7M flat YoY; Q4 net loss $23.5M.","Initiated IND-enabling for ABS-101 (anti-TL1A); IND expected Q1 2025.","Signed AstraZeneca collaboration for up to $247M in milestones plus royalties.","Raised $86.4M in common stock offering; cash $97.7M at Dec 31; runway into H1 2027.","Appointed Sir Menelas Pangalos to Board and co-chair of Scientific Advisory Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-012365","json":"https://secwatch.observer/filing/0001628280-24-012365.json","markdown":"https://secwatch.observer/filing/0001628280-24-012365.md","text":"https://secwatch.observer/filing/0001628280-24-012365.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000162828024012365/0001628280-24-012365-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000162828024012365/absc-20240321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:55:51.096121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ba87f6df33cfd595f681f50ef75f4183ededf1ac","claim":"Absci Corp reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On March 21, 2024, Absci Corporation (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672688/000162828024012365/0001628280-24-012365-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}